Role of antimüllerian hormone as a biomarker of the menopausal transition

Menopause

Volumn 20, Issue 2, 2013, Pages 218-222

  Kaori, Iino ^a   Ayako, Tarakida ^a   Kazuhiro, Abe ^a   Ryosuke, Taniguchi ^a   Tsuyoshi, Higuchi ^a   Ippei, Takahashi ^b   Hideki, Mizunuma ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Antim llerian hormone; Menopausal transition; Stages of Reproductive Aging Workshop

Indexed keywords

BIOLOGICAL MARKER; MUELLERIAN INHIBITING FACTOR;

ADULT; AMENORRHEA; AMH GEN II ASSAY KIT; ARTICLE; BLOOD SAMPLING; CLIMACTERIUM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JAPAN; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION; PATIENT SELECTION; SENSITIVITY AND SPECIFICITY; SERUM;

ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; HUMANS; JAPAN; LONGITUDINAL STUDIES; MENOPAUSE; MIDDLE AGED;

EID: 84873405915     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182611574     Document Type: Article

References (44)

1. Cate RL,Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, et al. Isolation of the bovine and human genes forMüllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986;45:685-698.
2. Josso N, Cate RL, Picard JY, Vigier B, di Clemente N, Wilson C, et al. Antimu ̈llerian hormone: the Jost factor. Recent Prog Horm Res 1993;48:1-59.
3. Rajpert-De Meyts E, JLrgensen N, Graem N,Müller J, Cate RL, Skakkebaek NE. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab 1999;84:3836-3844.
4. Hagen CP, Aksglaede L, SLrensen K, Main KM, Boas M, Cleemann L, et al. Serum levels of anti-Mü llerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab 2010;95:5003-5010.
5. Meduri G, Massin N, Guibourdenche J, Bachelot A, Fiori O, Kuttenn F, et al. Serum anti-Mü llerian hormone expression in women with premature ovarian failure. Hum Reprod 2007;22:117-123.
6. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mü llerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83.
7. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 2006;131:1-9.
8. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction 2002;124:601-609.
9. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Mü llerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891-4899.
10. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimu ̈llerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77:357-362.
11. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum Müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468-471.
12. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BCJM, Bancsi LFJMM, et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065-3071.
13. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 2011;95:170-175.
14. Fanchin R, Schonäuer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323-327.
15. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006;91:4057-4063.
16. Yang YS, Hur MH, Kim SY, Young K. Correlation between sonographic and endocrine markers of ovarian aging as predictors for late menopausal transition. Menopause 2011;18:138-145.
17. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Mü llerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007;22:766-771.
18. Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005;20:923-927.
19. van Disseldorp J, Faddy MJ, Themmen AP, de Jong FH, Peeters PH, van der Schouw YT, et al. Relationship of serum antimü llerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008;93: 2129-2134.
20. Tehrani FR, Solaymani-Dodaran M, Azizi F. A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause. Menopause 2009;16:797-802.
21. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Stages of Reproductive Aging Workshop (STRAW). J Womens Health 2001;10:843-848.
22. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, UT, July 2001. Menopause 2001;8:402-407.
23. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4:267-272.
24. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76:874-878.
25. Treloar AE. Menstrual cyclicity and the pre-menopause. Maturitas 1981;3:249-264.
26. Morabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol 1998; 148:1195-1205.
27. Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A. Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol 1998;51:1271-1276.
28. Harlow BL, Signorello LB. Factors associated with early menopause. Maturitas 2000;35:3-9.
29. Yasui T, Hayashi K, Mizunuma H, Kubota T, Aso T, Matsumura Y, et al. Association of endometriosis-related infertility with age at menopause. Maturitas 2011;69:279-283.
30. Shelling AN. Premature ovarian failure. Reproduction 2010;140:633-641.
31. Santoro N, Brockwell S, Johnston J, Crawford SL, Gold EB, Harlow SD, et al. Helping midlife women predict the onset of the final menses: SWAN, the Study of Women's Health Across the Nation. Menopause 2007;14:415-424.
32. Sowers MR, La Pietra MT. Menopause: its epidemiology and potential association with chronic diseases. Epidemiol Rev 1995;17:287-302.
33. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009;54:2366-2373.
34. Neer RM, Investigators S. Bone loss across the menopausal transition. Ann N Y Acad Sci 2010;1192:66-71.
35. Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008;93:3478-3483.
36. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause 2012;19:387-395.
37. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric 2012;15:105-114.
38. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012;97:1159-1168.
39. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Fertil Steril 2012;97:843-851.
40. Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE. Development of a second generation anti-Müllerian hormone (AMH) ELISA. J Immunol Methods 2010;362:51-59.
41. Wallace AM, Faye SA, Fleming R, Nelson SM. A multicentre evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II). Ann Clin Biochem 2011;48(pt 4):370-373.
42. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 2011;23:411-420.
43. Harlow SD, Cain K, Crawford S, Dennerstein L, Little R, Mitchell ES, et al. Evaluation of four proposed bleeding criteria for the onset of late menopausal transition. J Clin Endocrinol Metab 2006;91:3432-3438.
44. Taffe J, Dennerstein L. Time to the final menstrual period. Fertil Steril 2002;78:397-403.